2seventy bio, Inc. (TSVT)
NASDAQ: TSVT · Real-Time Price · USD
5.00
+0.01 (0.20%)
At close: May 12, 2025, 4:00 PM
5.00
0.00 (0.00%)
After-hours: May 12, 2025, 4:00 PM EDT
2seventy bio Revenue
2seventy bio had revenue of $22.94M in the quarter ending March 31, 2025, with 84.46% growth. This brings the company's revenue in the last twelve months to $48.37M, down -32.07% year-over-year. In the year 2024, 2seventy bio had annual revenue of $37.86M, down -62.28%.
Revenue (ttm)
$48.37M
Revenue Growth
-32.07%
P/S Ratio
5.41
Revenue / Employee
$744,077
Employees
65
Market Cap
265.62M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TSVT News
- 5 days ago - 2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb - Business Wire
- 25 days ago - 2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT - Business Wire
- 6 weeks ago - 2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 2 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc. - PRNewsWire
- 2 months ago - Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal - Benzinga
- 2 months ago - Top 3 Health Care Stocks That May Keep You Up At Night In Q1 - Benzinga
- 2 months ago - Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million - Reuters
- 2 months ago - 2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire